Valuation: TG Therapeutics, Inc.

Market Cap 7.94B 6.98B 6.49B 5.95B 11.18B 765B 11.36B 77.03B 30.1B 376B 29.81B 29.17B 1,300B P/E 2026 *
42.4x
P/E 2027 * 18.4x
Enterprise Value 7.94B 6.97B 6.48B 5.95B 11.18B 764B 11.35B 76.99B 30.08B 376B 29.8B 29.16B 1,299B EV / Sales 2026 *
8.42x
EV / Sales 2027 * 5.68x
Free-Float
88.55%
Yield 2026 *
-
Yield 2027 * -
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating MT
07-06 TG Therapeutics Initiates Phase 2 Trial Evaluating BRIUMVI In Patients With Treatment-Resistant Schizophrenia CI
07-06 TG Therapeutics Begins Phase 2 Trial of Briumvi in Treatment-Resistant Schizophrenia MT
06-09 TG Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02:00 PM
06-09 TG Therapeutics Reports Positive Topline Phase 1 Data For Subcutaneous BRIUMVI In Patients With Myasthenia Gravis and Initiates Potential Registration Directed Randomized Phase 2 Trial CI
06-09 TG Therapeutics Begins Phase 2 Myasthenia Gravis Trial MT
06-03 TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy MT
06-03 TG Therapeutics, Inc. Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous BRIUMVI CI
06-01 TG Therapeutics announces publication of post-hoc data from the phase 3 Ultimate I & II trials in treatment naive patients with relapsing forms of MS published in Frontiers in Immunology RE
06-01 TG Therapeutics, Inc. Publishes Post-Hoc Data from Phase 3 Ultimate I and Ii Trials Evaluating Briumvi in Treatment-Naïve Patients with Relapsing Multiple Sclerosis CI
05-27 Tg Therapeutics Announces Positive Topline Results from Phase 3 Enhance Trial CI
05-27 TG Therapeutics Says Phase 3 Briumvi Trial Met Main Goal MT
1 day+0.97%
1 week+2.13%
Current month+2.00%
1 month+4.49%
3 months+53.03%
6 months+79.62%
Current year+87.99%
1 week 51.28
Extreme 51.28
56.45
1 month 51.15
Extreme 51.15
59.3
Current year 26.76
Extreme 26.76
59.3
1 year 25.28
Extreme 25.28
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 2011-12-28
Director of Finance/CFO 44 2011-12-28
Investor Relations Contact - 2011-11-30
Director TitleAgeSince
Chairman 60 2011-12-28
Director/Board Member 79 2012-02-29
Director/Board Member 62 2012-11-08
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Free

Director

8,325 0.0054%
6/11/26 Free

Director

8,325 0.0054%
6/11/26 Free

Director

8,325 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%+2.13%+51.87%+178.25% 7.94B
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.54%+1.41%+28.77%+64.95% 365.09B
Weighted average by Cap. +0.76%+1.95%+36.03%+78.37%

Financials

2026 *2027 *
Net sales 942M 828M 770M 706M 1.33B 90.75B 1.35B 9.14B 3.57B 44.62B 3.54B 3.46B 154B 1.29B 1.13B 1.06B 969M 1.82B 124B 1.85B 12.53B 4.9B 61.18B 4.85B 4.75B 212B
Net income 207M 182M 169M 155M 292M 19.93B 296M 2.01B 784M 9.8B 777M 760M 33.88B 481M 423M 393M 361M 678M 46.36B 688M 4.67B 1.82B 22.79B 1.81B 1.77B 78.8B
Net Debt -4.69M -4.12M -3.83M -3.52M -6.61M -452M -6.71M -45.5M -17.78M -222M -17.61M -17.23M -768M -601M -528M -491M -451M -847M -57.9B -860M -5.83B -2.28B -28.47B -2.26B -2.21B -98.42B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
26-07-24 US$56.04 +0.97% 1,435,705
26-07-23 US$55.50 +5.35% 2,961,244
26-07-22 US$52.68 -2.35% 1,334,848
26-07-21 US$53.95 -0.02% 1,489,680
26-07-20 US$53.96 -1.66% 1,029,099
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
56.04USD
Average target price
64.00USD
Spread / Average Target
+14.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock